BRAF and metastatic colorectal cancer: According to authoritative guidelines such as the National Comprehensive Cancer Network (NCCN), the standard third-line therapy for microsatellite stable (MSS) metastatic colorectal cancer (mCRC) with RAS and BRAF mutations includes regorafenib, fruquintinib, and TAS-102 (1).